Cover Image
市場調查報告書

糖蛋白41 (gp41) :開發中產品分析

Glycoprotein 41 (gp41) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 363121
出版日期 內容資訊 英文 73 Pages
訂單完成後即時交付
價格
Back to Top
糖蛋白41 (gp41) :開發中產品分析 Glycoprotein 41 (gp41) - Pipeline Review, H2 2016
出版日期: 2016年10月12日 內容資訊: 英文 73 Pages
簡介

本報告提供糖蛋白41 (gp41)的開發情形調查分析,提供您開發中產品的概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等系統性資訊。

目錄

簡介

概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各適應症

開發中產品的概要

  • 後期階段的產品
  • 初期階段的產品

開發中的產品:各企業

開發中的產品:各大學/研究機關

治療藥的評估

  • 單劑/聯合治療別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Amunix Operating Inc.
  • BioClonetics Immunotherapeutics, Inc.
  • Frontier Biotechnologies Co., Ltd
  • InnaVirVax SA
  • Laboratorios Del Dr. Esteve S.A.
  • Longevity Biotech, Inc
  • Mymetics Corporation
  • Navigen Pharmaceuticals, Inc.
  • Osel, Inc.
  • Pharis Biotec GmbH

藥物簡介

暫停的計劃

最新消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0583TDB

Summary

Global Markets Direct's, 'Glycoprotein 41 (gp41) - Pipeline Review, H2 2016', provides in depth analysis on Glycoprotein 41 (gp41) targeted pipeline therapeutics.

The report provides comprehensive information on the Glycoprotein 41 (gp41), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glycoprotein 41 (gp41) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Glycoprotein 41 (gp41)
  • The report reviews Glycoprotein 41 (gp41) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Glycoprotein 41 (gp41) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Glycoprotein 41 (gp41) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Glycoprotein 41 (gp41) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Glycoprotein 41 (gp41)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Glycoprotein 41 (gp41) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Glycoprotein 41 (gp41) Overview
  • Therapeutics Development
    • Glycoprotein 41 (gp41) - Products under Development by Stage of Development
    • Glycoprotein 41 (gp41) - Products under Development by Therapy Area
    • Glycoprotein 41 (gp41) - Products under Development by Indication
  • Glycoprotein 41 (gp41) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Glycoprotein 41 (gp41) - Products under Development by Companies
  • Glycoprotein 41 (gp41) - Products under Development by Universities/Institutes
  • Glycoprotein 41 (gp41) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Glycoprotein 41 (gp41) - Companies Involved in Therapeutics Development
    • Amunix Operating Inc.
    • BioClonetics Immunotherapeutics, Inc.
    • ConjuChem, LLC
    • Frontier Biotechnologies Co., Ltd
    • InnaVirVax SA
    • Longevity Biotech, Inc
    • Mymetics Corporation
    • Navigen Pharmaceuticals, Inc.
    • Osel, Inc.
    • Pharis Biotec GmbH
  • Glycoprotein 41 (gp41) - Drug Profiles
    • Biologic for Infectious Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CLONE-3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CPT-31 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DAC-HIV - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DS-007 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Enfuvirtide-XTEN - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FB-006M - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HIV-1 vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LBT-5001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Target GP120 and GP41 for HIV - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MYMV-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MYMV-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Peptides for HIV-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Target GP120 and Gp41 for HIV-1 Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • STOP-3S - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide to Target gp41 for HIV Infection - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Inhibit GP120, GP41, Tat, Integrase and Protease for HIV-1 Infection - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VAC-02 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VAC-3S - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VIR-576 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Glycoprotein 41 (gp41) - Dormant Projects
    • Glycoprotein 41 (gp41) - Featured News & Press Releases
      • Sep 19, 2016: Mymetics and Texas Biomedical Research Institute Continue Collaboration on HIV Vaccine Development
      • Jun 06, 2016: Frontier Biotech Long-acting HIV-1 Fusion Inhibitor Albuvirtide Meets 48-Week Primary Objective: Interim Results of a Phase 3 Trial
      • Apr 11, 2016: Mymetics' HIV vaccine candidate confirms promise in preclinical study with Texas Biomed
      • Jul 30, 2015: Encouraging results of the first clinical study of the VAC-3S vaccine against HIV, for which DIAXONHIT develops a companion diagnostic
      • Apr 30, 2015: Texas Biomed receives NIH grant to study papillomavirus-based AIDS vaccine
      • Oct 28, 2014: Amunix and PolyPeptide Enter Into Partnership to Produce XTEN Peptide Conjugates for Evaluation by Third Parties for Pharmaceutical Therapeutics
      • Jul 23, 2014: Amunix and PolyPeptide Publish Multivalent Antiviral XTEN-Peptide Conjugates in vivo Studies in American Chemical Society's Journal "Bioconjugate Chemistry"
      • Dec 01, 2013: InnaVirVax Initiates Phase 2 Clinical Trial Evaluating VAC-3S, A Therapeutic Vaccine Used in Combination With Standard Antiretroviral Therapy in Treatment of HIV-Infection
      • Mar 05, 2013: InnaVirVax Presents Results From Phase I/IIa Clinical Study Of VAC-3S At CROI 2013
      • Feb 21, 2013: Mymetics Announces Publication Of Positive Phase I Study Results Of HIV-1 Vaccine In PLOS ONE
      • Nov 30, 2012: InnaVirVax's HIV Vaccine VAC-3S Achieves Primary End Point In Phase I/IIa Study
      • Jun 18, 2012: InnaVirVax Files New European Patent Application For VAC-3S Immunotherapy
      • Mar 05, 2012: InnaVirVax Initiates Phase I/IIa Clinical Trial Of VAC-3S For Treatment Of HIV Infections
      • Oct 13, 2011: InnaVirVax Obtains Authorization From French Drug Agency To Start Phase I/IIa Study Of VAC-3S
      • Jun 22, 2011: InnaVirVax Announces Positive Preclinical Results Of VAC-3S For Treatment Of HIV Infections
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by Amunix Operating Inc., H2 2016
  • Pipeline by BioClonetics Immunotherapeutics, Inc., H2 2016
  • Pipeline by ConjuChem, LLC, H2 2016
  • Pipeline by Frontier Biotechnologies Co., Ltd, H2 2016
  • Pipeline by InnaVirVax SA, H2 2016
  • Pipeline by Longevity Biotech, Inc, H2 2016
  • Pipeline by Mymetics Corporation, H2 2016
  • Pipeline by Navigen Pharmaceuticals, Inc., H2 2016
  • Pipeline by Osel, Inc., H2 2016
  • Pipeline by Pharis Biotec GmbH, H2 2016
  • Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top